Advertisement
Research Article

Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer

  • Kelly Coffey,

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Timothy J. Blackburn,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Susan Cook,

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Bernard T. Golding,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Roger J. Griffin,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Ian R. Hardcastle,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Lorraine Hewitt,

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Kety Huberman,

    Affiliation: OSI Pharmaceuticals, Inc, Farmingdale, New York, United States of America

    X
  • Hesta V. McNeill,

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • David R. Newell,

    Affiliation: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Celine Roche,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Claudia A. Ryan-Munden,

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Anna Watson,

    Affiliations: Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom, Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Craig N. Robson mail

    c.n.robson@ncl.ac.uk

    Affiliation: Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    X
  • Published: October 08, 2012
  • DOI: 10.1371/journal.pone.0045539

About the Authors

Kelly Coffey, Susan Cook, Lorraine Hewitt, Hesta V. McNeill, Claudia A. Ryan-Munden, Craig N. Robson
Solid Tumour Target Discovery Laboratory, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom
Timothy J. Blackburn, Bernard T. Golding, Roger J. Griffin, Ian R. Hardcastle, David R. Newell, Celine Roche, Anna Watson
Drug Discovery and Imaging Group, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom
Kety Huberman
OSI Pharmaceuticals, Inc, Farmingdale, New York, United States of America
Timothy J. Blackburn, Bernard T. Golding, Roger J. Griffin, Ian R. Hardcastle, Celine Roche, Anna Watson
Research and School of Chemistry, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

Corresponding Author

Email: c.n.robson@ncl.ac.uk

Competing Interests

KH was employed by OSI Pharmaceuticals, Inc. Compounds discussed in this article are not patented, in development or being marketed by this company. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: KC IRH RJG BTG CNR. Performed the experiments: LH HVM SC KC TJB BTG RJG IRH KH CR AW DRN CARM. Analyzed the data: KC CNR. Wrote the paper: KC TJB BTG RJG IRH DRN CNR KC.